FDA Places Partial Clinical Hold on Selinexor Trials

March 14, 2017 – The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types. Although the hold stops additional enrollment in the trials, patients who have achieved stable disease (SD) or better can continue treatment, according to Karyopharm, the company developing the agent. “The FDA has indicated that the partial clinical hold is due to incomplete information in the existing version of the investigator’s … (leggi tutto)